Invesco DB Commodity Index Tracking Fund vs Guardant Health Inc. Common Stock — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $32.8 (market cap $1.93B), while Guardant Health Inc. Common Stock trades at $165.58 (market cap $22.58B). The key difference: Guardant Health Inc. Common Stock is far larger — about 11.7× Invesco DB Commodity Index Tracking Fund's market cap, and Invesco DB Commodity Index Tracking Fund is more actively traded (569,977 versus 2,200,599). Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 61 Days and Guardant Health Inc. Common Stock for 0 Days on average.
| DBC | GH | |
|---|---|---|
Market Cap | $1.93B | $22.58B |
Volume | 569,977 | 2,200,599 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $187.22 |
52-Week Low | $22.07 | $61.73 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $23.22B |
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% on the day, with a bullish technical signal from moving averages. The company reported $82.59M in revenue and $22.38M net income for 2024, showing improved profitability from 2023's loss. Cash flow from operations was strong at $431.54M, contributing to a healthy balance sheet with $1.28B in shareholder equity and minimal debt.
The outlook appears favorable with positive earnings momentum and robust operational cash flow. Key risks include revenue volatility, as seen in historical fluctuations, and dependence on commodity market conditions. Analyst sentiment is constructive given the bullish technical indicators and improved financial performance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →